CN107129506B - As pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives of EGFR inhibitor and its application - Google Patents
As pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives of EGFR inhibitor and its application Download PDFInfo
- Publication number
- CN107129506B CN107129506B CN201610107775.8A CN201610107775A CN107129506B CN 107129506 B CN107129506 B CN 107129506B CN 201610107775 A CN201610107775 A CN 201610107775A CN 107129506 B CN107129506 B CN 107129506B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- egfr
- phenyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to as EGFR inhibitor pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives and its application.Specifically, the purposes the present invention relates to compound shown in Formulas I, pharmaceutical composition containing a compound of formula I and the compound in preparation treatment EGFR related disease or the drug for inhibiting EGFR:
Description
Technical field
The present invention relates to field of medicinal chemistry；Specifically, the present invention relates to novel Isosorbide-5-Nitrae-dihydro -2H- pyrimido [4,
5-d] [1,3] oxazines -2- ketone derivatives, synthetic method and its as EGFR inhibitor in the drug for preparing tumor-related illness
In application.
Background technique
Cancer is also known as malignant tumour, is the major class disease with the characteristics of abnormal cell proliferation and transfer, has disease incidence
The high and high feature of the death rate is to threaten human health, leads to dead one of malignant disease.Data shows 2008
There are 12,700,000 cancer patients in the whole world, and wherein death toll is up to more than 700 ten thousand.And the new hair tumour patient in the whole world 20% is in
State, 24% tumor mortality patient is in China.If not adopting an effective measure prevention, or take out more preferably therapeutic scheme, it is contemplated that
To the year two thousand thirty, will occur 26,000,000 newly-increased cases of cancer in world wide every year, number of cancer deaths is up to 17,000,000.Existing
In some cancers, lung cancer is the highest malignant tumour of morbidity and mortality in current world wide, wherein non-small cell lung cancer
(NSCLC) 80% or more of patients with lung cancer is accounted for.It is predicted according to the World Health Organization (WHO), by 2025, China increased lung cancer newly every year
Case will be more than 1,000,000.Once being diagnosed as lung cancer, patient just only has remote survival prospects, and survival rate is less than 15% within 5 years.
Since the 1980s, with going deep into for oncomolecularbiology research, the molecule machine of tumorigenesis
It is increasingly clear to make.In many factors for inducing cancer, highly expressed certain albumen as caused by gene mutation swash in cancer cell
Enzyme is one of the principal element for leading to its signal transduction pathway exception.Protein tyrosine kinase is the weight in signal transduction process
Want the factor, participate in a series of cellular activities, grow, break up with cell, be proliferated it is closely related.The γ phosphate that it is catalyzed ATP turns
It moves on on the tyrosine residue of many key proteins, makes phenolic hydroxyl group phosphorylation, to transmit signal.Therefore, development selectivity
Kinases inhibitor come block or regulate and control the disease generated extremely due to these signal paths have been considered as it is antitumor
One effective research strategy of drug development.In numerous tyrosine kinase, epidermal growth factor recipient tyrosine kinase
(epidermal growth factor receptor tyrosine kinase, EGFR) is indispensable important composition portion
Point.EGFR is made of 1186 amino acid, encodes the transmembrane glycoprotein that a molecular weight is 170-kDa.EGFR can mediate more
Bars Signal Transduction Pathways, extracellular signal are transmitted to intracellular, are sent out the proliferation of normal cell and tumour cell, differentiation and apoptosis
Wave important adjustment effect (Cell, 2000,100,113-127).EGFR is many normal epithelial tissues (such as skin and hair follicle)
Constructive expression's ingredient, and in most of solid tumor, EGFR, which exists, to be overexpressed or high expression.For example, in lung cancer,
The expression rate of EGFR reaches 40~80%.Therefore selectively inhibit EGFR, the signal transduction pathway for interfering it to mediate, Ke Yida
To the purpose for the treatment of lung cancer, a practical way is opened for targeted therapy of lung cancer.
On clinical treatment, in conjunction with traditional radiotherapy, chemotherapy, with EGFR targeted drug such as Gefitinib (Iressa), E Luo
Carry out first-line drug for Buddhist nun (Tarceva) etc. is proved to be very effective in lung cancer therapy.However, clinical practice shows:
Most of Patients with Non-small-cell Lung can be occurred acquired after using Gefitinib or Tarceva treatment within the 6-12 month
Drug resistance.Wherein mutation (790 Soviet Union's ammonia of the drug resistance of about 60% case and an amino acid residue in EGFR kinase domain
Sour residue mutations are methionine, T790M) related (The New England Journal of Medicine, 2005,352,
786-792).T790M mutation cause inhibitor with EGFR ining conjunction with when generation steric hindrance or increase EGFR and ATP it is affine
Power, so that the anticancer effect for the competitive inhibitor that this kind of invertibity combines weakens significantly.The generation of drug resistance not only reduces
Patient has been greatly reduced the life quality of tumor patient to the sensibility of drug.Drug resistance caused by order to overcome T790M to be mutated
Property, a series of irreversible ATP competitive inhibitors (such as CI-1033, HKI-272, PF00299804) have entered clinical research
Stage.Irreversible inhibitor contains a michael acceptor segment, can be with a conserved amino acid of the ATP-binding site of EGFR
Residue (Cys797) forms covalent bond, to obtain EGFR binding affinity more stronger than reversible inhibitor.Nevertheless,
Since such drug is selectively poor to wild type and mutant egf R, maximal tolerance dose (MTD) is lower, clinical trial
Effect is not obvious.
Therefore, research and development selective depression T790M mutation, overcomes the third generation EGFR targeted drug of clinical drug-resistant to have
Great clinical meaning and application prospect.
Summary of the invention
It is completely new the purpose of the present invention is to provide a kind of structure, can selective depression T790M be mutated and overcome clinic
The third generation EGFR inhibitor of drug resistance.
In a first aspect, the present invention provides general formula I compound represented or its optical isomer or pharmaceutically acceptable
Salt:
In formula, A is phenyl ring, five yuan or hexa-member heterocycle, C3-C8Naphthenic base；
R1It is each independently selected from hydrogen, halogen, C1-C3Alkoxy, C1-C3Alkyl, C1-C4Alkylamidoalkyl, substituted piperazinyl,
Replace high piperazine base, replaces morpholinyl, replaces thio-morpholinyl, 4-N- methyl piperazine base, 4-N- acetylpiperazinyl, 4-N, N-
Lupetidine base, substituted piperidine base, N, N, N'- trimethyl ethylenediamine base, N, N- dimethyl ethanol amido, 1- methyl -4- (piperazine
Pyridine) piperazinyl ,-NRaRb, wherein RaAnd RbIt can be selected from alkyl and containing azanyl；
R2It is each independently selected from following group:
R3、R4It is each independently selected from the following group: hydrogen, C1-C10Alkyl, substituted C1-C10Alkyl, the C optionally replaced3-C8Cycloalkanes
Base, the benzyl optionally replaced, the heterocycle optionally replaced；
B is selected from the group:
M is the integer of 0-7.
In a particular embodiment, the compound is as shown in general formula II:
In formula, B, R1、R2、R3、R4As defined in claim 1；
M is the integer of 0-5.
In further embodiment, the compound is as shown in general formula III:
In formula,
R2It is selected from
R3、R4It is each independently selected from H or C1-C6Alkyl, preferably methyl or ethyl；
R5、R6、R7、R8And R9It is independently selected from the following group:
In further embodiment, R6、R8And R9For H.
In second aspect, the present invention provides compound or its optical isomer or pharmaceutically acceptable selected from the group below
Salt:
In a particular embodiment, the present invention provides compound selected from the group below:
In the third aspect, the present invention provides a kind of pharmaceutical composition, and described pharmaceutical composition contains first aspect present invention
The compound or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier or excipient.
In a preferred embodiment, described pharmaceutical composition is adapted for oral dosage form, including but not limited to tablet, molten
Liquor, suspension, capsule, granule, pulvis.
In fourth aspect, the present invention provides compound described in first aspect present invention and treats or prevents EGFR Jie in preparation
Purposes in the disease led, or the drug of inhibition EGFR.
In a particular embodiment, the disease that the EGFR is mediated is cancer.
In further embodiment, the cancer is selected from the group: non-small cell lung cancer, Small Cell Lung Cancer, lung
Gland cancer, lung squamous cancer, breast cancer, prostate cancer, neurogliocytoma, oophoroma, G. cephalantha, cervical carcinoma, the cancer of the esophagus, liver
Cancer, kidney, cancer of pancreas, colon cancer, cutaneum carcinoma, leukaemia, lymthoma, gastric cancer, multiple bone marrow cancer and solid tumor.
At the 5th aspect, the present invention, which is provided, treats or prevents EGFR mediation using compound described in first aspect present invention
Disease method.
In a preferred embodiment, the disease that the EGFR is mediated is cancer；Preferably, the cancer is selected from the group:
Non-small cell lung cancer, Small Cell Lung Cancer, adenocarcinoma of lung, lung squamous cancer, breast cancer, prostate cancer, neurogliocytoma, oophoroma,
It is G. cephalantha, cervical carcinoma, the cancer of the esophagus, liver cancer, kidney, cancer of pancreas, colon cancer, cutaneum carcinoma, leukaemia, lymthoma, gastric cancer, more
Hair property bone marrow cancer and solid tumor.
It should be understood that above-mentioned each technical characteristic of the invention and having in below (eg embodiment) within the scope of the present invention
It can be combined with each other between each technical characteristic of body description, to form a new or preferred technical solution.As space is limited, exist
This no longer tires out one by one states.
Specific embodiment
Inventor after extensive and in-depth study, it was unexpectedly found that a collection of structure it is completely new Isosorbide-5-Nitrae-dihydro -2H- it is phonetic
Pyridine simultaneously [4,5-d] [1,3] oxazines -2- ketone derivatives, these derivatives can selective depression EGFR T790M mutation, it is right
EGFRT790M/L858RThe IC of kinase inhibiting activity50Value reaches nM rank；To cancer cell (EGFRL858R/T790MMutation) proliferation inhibition
Active IC50Value also reaches nM rank.The present invention is completed on this basis.
The present inventor has synthesized the candidate compound with EGFR inhibitory activity.Structure is carried out to obtained candidate compound
Optimization has designed and synthesized and a series of has had no Isosorbide-5-Nitrae reported in the literature-dihydro -2H- pyrimido [4,5-d] [1,3] oxazines -2- ketone
Class compound, and carry out finishing structure characterization.The active testing that molecular level and cellular level have been carried out to this series compound, obtains
There is the compound of selective depression EGFR T790M mutation to a batch.Wherein compound 006 is to EGFRT790M/L858Kinase inhibition
Active IC50For 4.5nM, H1975 (non-small cell lung cancer cell, EGFRL858R/T790M) cell inhibitory effect activity IC50For
100nM；In addition, the compound of the present invention shows different inhibition from the cell of EGFR saltant type for the cell of EGFR wild type
Activity, wherein IC of the compound 002 for the cell of EGFR wild type and the cell of EGFR saltant type50The ratio between value is greater than 20, changes
Close the above-mentioned IC of object 00650The ratio between value is close to 10, it is meant that the compound may have very excellent difference toxicity in vivo.
Term definition
The some group definitions being referred to herein are as follows:
Herein, " alkyl " refers to that carbon chain lengths are the branched-chain or straight-chain alkyl of the saturation of 1-10 carbon atom, preferred alkane
Base includes long 2-8,1-6,1-4,3-8, the alkyl of 1-3 carbon atom not etc..The example of alkyl includes but is not limited to:
Methyl, ethyl, n-propyl, isopropyl, normal-butyl, isobutyl group, heptyl etc..Alkyl can be replaced by one or more substituent groups, example
Such as replaced by halogen or halogenated alkyl.It can be for example, alkyl can be by the alkyl or alkyl that 1-4 fluorine atom replaces
The alkyl replaced by fluoro-alkyl.
Herein, " naphthenic base " refers to the cyclic alkyl of the saturation using carbon atom as annular atom.In preferred embodiment party
In formula, the naphthenic base includes the naphthenic base for having 3-8 carbon atom as annular atom, such as (but not limited to) cyclopropyl, ring
Butyl, cyclopenta, cyclohexyl, suberyl, cyclooctyl.
Herein, " alkoxy " refers to by alkyl-substituted oxygroup.Preferred alkoxy is the alcoxyl of long 1-6 carbon atom
Base, the alkoxy of more preferably long 1-4 carbon atom.The example of alkoxy includes but is not limited to: methoxyl group, ethyoxyl, the third oxygen
Base etc..
Herein, " halogen " refers to fluorine, chlorine, bromine and iodine.
" heterocycle " used herein includes but is not limited to the heteroatomic 5- or 6-membered heterocycle that O, S or N are selected from containing 1-3
Group, including but not limited to furyl, thienyl, pyrrole radicals, pyrrolidinyl, pyrazolyl, imidazole radicals, triazolyl, oxazolyl, pyrrole
It mutters base, pyridyl group, pyrimidine radicals, pyrazinyl, piperidyl, morpholinyl etc..
Herein, " acylamino- " refers to that structural formula is the group of "-R '-NH-C (O)-R ", wherein R ' can be selected from hydrogen or alkyl,
R can be selected from alkyl, alkenyl, alkynyl, by NRcRdSubstituted alkyl, by NRcRdSubstituted alkenyl and NRcRdSubstituted alkynyl,
The alkyl being optionally substituted by halogen, the alkenyl replaced by cyano, wherein RcAnd RdIt can be selected from alkyl and alkenyl.
Herein, " optionally replace " and refer to that the substituent group that it is modified is optionally a (for example, 1,2,3,4 or 5 by 1-5
It is a) substituent group substitution selected from the following: halogen, C1-4Aldehyde radical, C1-6Linear or branched alkyl group, cyano, nitro, amino, hydroxyl, hydroxyl
Alkoxy (such as trifluoromethoxy), the carboxyl, C of alkyl (such as trifluoromethyl), halogen substitution that methyl, halogen replace1-4Alkane
Oxygroup, ethoxycarbonyl, N (CH3) and C1-4Acyl group.
The compound of the present invention
The compound of the present invention is following general formula I compound represented or its pharmaceutically acceptable salt:
In formula, A is phenyl ring, five yuan or hexa-member heterocycle, C3-C8Naphthenic base；
R1It is each independently selected from hydrogen, halogen, C1-C3Alkoxy, C1-C3Alkyl, C1-C4Alkylamidoalkyl, substituted piperazinyl,
Replace high piperazine base, replaces morpholinyl, replaces thio-morpholinyl, 4-N- methyl piperazine base, 4-N- acetylpiperazinyl, 4-N, N-
Lupetidine base, substituted piperidine base, N, N, N'- trimethyl ethylenediamine base, N, N- dimethyl ethanol amido, 1- methyl -4- (piperazine
Pyridine) piperazinyl ,-NRaRb, wherein RaAnd RbIt can be selected from alkyl and containing azanyl；
R2It is each independently selected from following group:
R3、R4It is each independently selected from the following group: hydrogen, C1-C10Alkyl, substituted C1-C10Alkyl, the C optionally replaced3-C8Cycloalkanes
Base, the benzyl optionally replaced, the heterocycle optionally replaced；
B is selected from the group:
M is the integer of 0-7.
In a particular embodiment, A ring is phenyl ring, so that the compound of the present invention is as shown in following general formula II:
In formula, B, R1、R2、R3、R4As described above；The integer for being 0-5 with m.
In a preferred embodiment, the above-mentioned phenyl ring in the compound of the present invention can be substituted or unsubstituted, example
Such as, the compound of the present invention can be as shown in following general formula III:
In formula,
R2It is selected from
R3、R4It is each independently selected from H or C1-C6Alkyl, preferably methyl or ethyl；
R5、R6、R7、R8And R9It is independently selected from the following group:
In further embodiment, the above-mentioned phenyl ring in the compound of the present invention can make ortho position substitution, meta position takes
Generation and/or contraposition replace.In a preferred embodiment, the above-mentioned phenyl ring in the compound of the present invention is ortho position substitution and contraposition
Replace.In a particular embodiment, the R in formula above III6、R8And R9For H.
The present inventor, which synthesizes to have obtained a series of structures, has no 1,4- dihydro -2H- pyrimido [4,5-d] reported in the literature
[1,3] oxazines -2- ketone compounds, specific compound are as follows:
In particular compound provided by the invention, with the difference of substituent group, it is former that there are chiral carbons in some compounds
Son, that is, there are optical isomers for some compounds.The present inventor has further split these optical isomers, as shown in the table:
On the basis of the compound of the present invention, the present invention provides a kind of pharmaceutical composition, and the composition, which contains treatment, to be had
The compound of the present invention of effect amount or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier or excipient.
The example of the pharmaceutically acceptable salt of the compounds of this invention includes but is not limited to inorganic and acylate, such as salt
Hydrochlorate, hydrobromate, sulfate, citrate, lactate, tartrate, maleate, fumarate, mandelate and grass
Hydrochlorate；And it is formed with alkali such as sodium hydroxyl, three (hydroxymethyl) aminomethanes (TRIS, amine butantriol) and N-METHYL-ALPHA-L-GLUCOSAMINE
Inorganic and organic alkali salt.
Although each Man's Demands are different, those skilled in the art can determine every kind of work in pharmaceutical composition of the present invention
The optimal dose of property ingredient.Under normal circumstances, the compound of the present invention or its pharmaceutically acceptable salt, it is daily to mammal
Oral administration, dose is according to about 0.0025 to 50 mg kg of body weights.It is preferred that about 0.01 to 10 milli of per kilogram oral administration
Gram.For example, unit oral doses may include about 0.01 to 50 milligrams, preferably about 0.1 to 10 milligrams of the compounds of this invention.
Unit dose can be given one or many, be daily one or more pieces, and every contains about 0.1 to 50 milligrams, and eligibly about 0.25
To 10 milligrams of the compounds of this invention or its solvate.
Pharmaceutical composition of the invention can be formulated into the dosage form for being suitble to various administration routes, including but not limited to quilt
It is configured to for parenteral, subcutaneously, vein, muscle is intraperitoneal, transdermal, oral cavity, intrathecal, encephalic, nasal cavity or topical route administration
Form, for treating tumour and other diseases.Dosage is the dose for effectively improving or eliminating one or more illnesss.For
The treatment of specified disease, effective quantity are the doses for being enough to improve or mitigate in some manner symptom related with disease.It is such
Dose can be used as single dose application, or can be administered according to effective therapeutic scheme.Dosage also permits healing disease, still
It is administered typically to the symptom for improving disease.Repetitively administered is generally required to realize that required symptom improves.The dosage of medicine will
According to the age of patient, health and weight, the type of concurrent treatment, the frequency for the treatment of and required treatment benefit are determined.
Pharmaceutical preparation of the invention can give any mammal, as long as they can obtain the treatment of the compounds of this invention
Effect.The most importantly mankind in these mammals.
The compound of the present invention or its pharmaceutical composition can be used for treating various by epidermal growth factor receptor kinase
(EGFR) disease mediated.It herein, is various cancers by the disease that EGFR is mediated.The cancer includes but is not limited to: non-small
Cell lung cancer, Small Cell Lung Cancer, adenocarcinoma of lung, lung squamous cancer, breast cancer, prostate cancer, neurogliocytoma, oophoroma, neck
It is portion's squamous carcinoma, cervical carcinoma, the cancer of the esophagus, liver cancer, kidney, cancer of pancreas, colon cancer, cutaneum carcinoma, leukaemia, lymthoma, gastric cancer, multiple
Bone marrow cancer and solid tumor.
Pharmaceutical preparation of the invention can manufacture in a known manner.For example, by traditional mixing, granulation, ingot processed, dissolution,
Or freezing dry process manufacture.When manufacturing oral preparation, in combination with solid adjuvant material and reactive compound, selective ground and mixed
Object.After if necessary or appropriate amount of addition agent being added when necessary, granulate mixture is processed, obtains tablet or pastille core.
Suitable auxiliary material especially filler, such as carbohydrate such as lactose or sucrose, mannitol or sorbierite；Cellulose preparation or
Calcium phosphate, such as tricalcium phosphate or calcium monohydrogen phosphate；And binder, such as gelatinized corn starch, including cornstarch, wheaten starch,
Rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methyl cellulose, sodium carboxymethylcellulose, or
Polyvinylpyrrolidone.If desired, can increase disintegrating agent, than starch as mentioned above and carboxymethyl starch, crosslinking is poly-
Vinylpyrrolidone, agar or alginic acid or its salt, such as sodium alginate.Adjuvant especially flowing regulator and lubricant, example
Such as, silica, talcum, stearates, such as magnesium calcium stearate, stearic acid or polyethylene glycol.If desired, pastille core can be given
The suitable coating that gastric juice can be resisted is provided.For this purpose, can be using concentration saccharide solution.This solution can contain Arabic tree
Glue, talcum, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide paint solution and suitable organic solvent or solvent mixing
Object.In order to prepare the coating of resistant to gastric juice, cellulose solution appropriate, such as cellulose acetate phthalic acid or hydroxypropyl can be used
Ylmethyl cellulose phthalic acid.Dyestuff or pigment can be added to the coating of tablet or pastille core.For example, for identification or
In order to characterize the combination of active constituent dosage.
Based on above compound and pharmaceutical composition, the present invention further provides a kind of sides of disease for treating EGFR mediation
Method, this method include giving the object of needs with the compound of the present invention or pharmaceutical composition.
Medication includes but is not limited to various medications well known in the art, can be subject to according to the actual conditions of patient
It determines.These methods are including but not limited to parenteral, subcutaneous, vein, muscle, intraperitoneal, transdermal, oral cavity, intrathecal, encephalic, nasal cavity
Or topical route administration.
The present invention also includes the disease or inhibition activity of EGFR that the compounds of this invention is mediated in preparation prevention or treatment EGFR
Drug in purposes.
Advantages of the present invention:
1. compound provided by the invention is a kind of 1,4- dihydro -2H- pyrimido [4,5-d] [1,3] that structure is completely new evil
Piperazine -2- ketone compound；
2. compound provided by the invention has excellent inhibitory activity to the cancer cell that mutant egf R or EGFR are mutated；
3. compound provided by the invention is that exploitation energy selective depression T790M is mutated, clinical drug-resistant can be overcome
EGFR targeted drug is laid a good foundation, and has great industrialization and commercialization prospect and market value, remarkable in economical benefits.
Technical solution of the present invention is further described below in conjunction with specific implementation case, but following case study on implementation is not constituted
Limitation of the present invention, the various method of administration that all principles and technological means according to the present invention use, belongs to the present invention
Range.In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition, or is built according to manufacturer
The condition of view.Unless otherwise stated, otherwise percentage and number are calculated by weight.
Materials and methods
The following institute of synthesis of 1,4- dihydro -2H- pyrimido [4,5-d] [1,3] oxazines -2- ketone compounds of the invention
Show:
Reagent and condition: (a) (3- aminophenyl) t-butyl carbamate, DIPEA, CH3CN, reflux, 6h；(b)
LiAlH4,THF,0℃,4h；(c)MnO2,CH2Cl2, room temperature, overnight；(d) Grignard Reagent, THF, 0 DEG C, 5h；(e)CDI,K2CO3,
THF flows back, overnight；(f) arylamine, trifluoroacetic acid, trifluoroethanol, reflux, for 24 hours；(g) trifluoroacetic acid, CH2Cl2, room temperature, 5h；
(h) acryloyl chloride, Et3N,CH2Cl2, 0 DEG C is arrived room temperature, overnight.
Embodiment 1
The specific synthetic method of above-mentioned steps a-h is as follows:
The synthesis of 4- 1. ((3- ((tert-butoxycarbonyl) amino) phenyl) amino) -2- chlorine pyrimidine -5- Ethyl formate
Weigh the chloro- 5- pyrimidinecarboxylic acid ethyl ester (22.100g, 100mmol) of 2,4- bis-, DIPEA (12.900g, 100mmol) in
The dissolution of 100mL acetonitrile is added in 500mL single-necked flask.Separately take (3- aminophenyl) t-butyl carbamate (20.800g,
It 100mmol) is dissolved in 100mL acetonitrile, is added drop-wise in above-mentioned reaction solution, reflux 6h is dripped.TLC tracks to raw material conversion, cooling
It to room temperature, filters, acetonitrile washing, it is phonetic to obtain 4- ((3- ((tert-butoxycarbonyl) amino) phenyl) amino) -2- chlorine for filter cake drying
Pyridine -5- Ethyl formate 33.710g.1H NMR(400MHz,DMSO-d6)δ10.23(s,1H),9.50(s,1H),8.80(s,1H),
7.70 (s, 1H), 7.35 (d, J=8.0Hz, 1H), 7.29 (t, J=8.0Hz, 1H), 7.23 (d, J=8.0Hz, 1H), 4.38
(q, J=7.2Hz, 2H), 1.49 (s, 9H), 1.36 (t, J=7.2Hz, 3H) .LC-MS:m/z:393.1 (M+H)+.
(2. 3-((2- chloro- 5- (methylol) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate
Weigh 4- ((3- ((tert-butoxycarbonyl) amino) phenyl) amino) -2- chlorine pyrimidine -5- Ethyl formate (31.360g,
80mmol) in 5000mL two mouth flask, 100mL anhydrous tetrahydro furan is added and dissolves, ice bath stirring 10 minutes.Separately take lithium aluminium hydride
(12.160g, 320mmol) is dissolved in 150mL anhydrous tetrahydro furan, is slowly dropped in above-mentioned reaction solution, is dripped ice bath and is stirred
It mixes 4 hours.TLC tracks raw material conversion, and reaction solution is instilled to 250mL saturation NH in batches4In Cl aqueous solution, ethyl acetate extraction,
Collected organic layer, anhydrous Na2SO4Dry, rotary evaporation removes solvent.Crude product is through silica gel column chromatography separating purification (petroleum ether/second
Acetoacetic ester=2:1, v/v).Obtain (3- ((2- chloro- 5- (methylol) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate
3.638g。1H NMR(400MHz,CDCl3) δ 8.38 (s, 1H), 7.87 (s, 1H), 7.70 (s, 1H), 7.34 (d, J=8.4Hz,
1H), 7.25 (t, J=8.0Hz, 1H), 7.05 (d, J=8.0Hz, 1H), 6.66 (s, 1H), 4.65 (s, 2H), 1.52 (s, 9H)
.LC-MS:m/z:351.1(M+H)+.
(3. 3-((the chloro- 5- formylpyrimidin-4- base of 2-) amino) phenyl) t-butyl carbamate
Weigh (3- ((2- chloro- 5- (methylol) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate (3.500g,
10mmol) in 100mL single-necked flask, the dissolution of 40mL methylene chloride is added.Be added portionwise manganese dioxide (58%, 15.000g,
100mmol), it is stirred overnight at room temperature.TLC tracks raw material conversion, pads suction filtered through kieselguhr, and filtrate is spin-dried for, and crude product is through silica gel column chromatography
Isolate and purify (petrol ether/ethyl acetate=4:1, v/v).Obtain (3- ((the chloro- 5- formylpyrimidin -4- base of 2-) amino) phenyl) ammonia
Base t-butyl formate 2.850g.1H NMR(400MHz,CDCl3)δ10.60(s,1H),9.89(s,1H),8.56(s,1H),7.82
(t, J=2.0Hz, 1H), 7.39 (d, J=8.8Hz, 1H), 7.31 (t, J=8.0Hz, 1H), 7.20 (d, J=8.0Hz, 1H),
6.58(s,1H),1.53(s,9H).LC-MS:m/z:349.1(M+H)+.
(4. 3- ((the chloro- 5- of 2- (1- ethoxy) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate
Weigh (3- ((the chloro- 5- formylpyrimidin -4- base of 2-) amino) phenyl) t-butyl carbamate (1.044g,
3mmol) in 50mL two mouth flask, the dissolution of 20mL anhydrous tetrahydro furan is added, argon gas is protected, and ice bath stirring 10 minutes.Separately take first
Base magnesium bromide (1M in THF, 9mL), is slowly added into above-mentioned reaction solution, drips ice bath stirring 5 hours.TLC tracking is former
Reaction solution is poured into 30mL saturation NH by material conversion4In Cl aqueous solution, ethyl acetate extraction, collected organic layer, anhydrous Na2SO4It is dry
Dry, rotary evaporation removes solvent.Crude product is through silica gel column chromatography separating purification (petrol ether/ethyl acetate=2:1, v/v).Obtain (3-
((the chloro- 5- of 2- (1- ethoxy) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate 0.831g.1H NMR(400MHz,
CDCl3) δ 8.83 (s, 1H), 7.77 (s, 1H), 7.70 (s, 1H), 7.29 (d, J=8.4Hz, 1H), 7.23 (t, J=8.0Hz,
1H), 7.05 (d, J=8.0Hz, 1H), 6.67 (s, 1H), 4.87 (q, J=6.4Hz, 1H), 1.55 (d, J=6.4Hz, 3H),
1.52(s,9H).LC-MS:m/z:365.1(M+H)+.
(5. 3- (chloro- 4- methyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (the 4H)-yl of 7-) phenyl) amino
T-butyl formate
Weigh (3- ((the chloro- 5- of 2- (1- ethoxy) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate (0.815g,
2.2mmol), potassium carbonate (0.455g, 3.3mmol), 1,1'- carbonyl dimidazoles (1.069g, 6.6mmol) are burnt in 25mL single port
Bottle is added 10mL anhydrous tetrahydro furan, is refluxed overnight.TLC tracks raw material conversion, and ice water, methylene chloride extraction is added, and collection has
Machine layer, anhydrous Na2SO4Dry, rotary evaporation removes solvent.Crude product is through silica gel column chromatography separating purification (petrol ether/ethyl acetate
=2:1, v/v).It obtains (3- (chloro- 4- methyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (the 4H)-yl of 7-) phenyl)
T-butyl carbamate 0.754g.1H NMR(400MHz,DMSO-d6)δ9.59(s,1H),8.54(s,1H),7.61(s,1H),
7.41-7.36 (m, 2H), 6.98 (d, J=6.8Hz, 1H), 5.86 (q, J=6.4Hz, 1H), 1.74 (d, J=6.4Hz, 3H),
1.47(s,9H).LC-MS:m/z:391.1(M+H)+.
6. ((7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4- methyl-2- oxo-2H- are phonetic by 3-
Pyridine simultaneously [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) t-butyl carbamate
Weigh (3- (chloro- 4- methyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (the 4H)-yl of 7-) phenyl) ammonia
Base t-butyl formate (0.737g, 1.89mmol), 2- methoxyl group -4- (4- methylpiperazine-1-yl) aniline (0.502g,
2.27mmol) in 50mL two mouth flask, the dissolution of 15mL trifluoroethanol is added, is added dropwise trifluoroacetic acid (210 μ L, 2.84mmol), argon
Gas shielded, temperature rising reflux 24 hours.TLC tracks raw material conversion, is cooled to room temperature, and saturation NaHCO is added3Aqueous solution is neutralized to alkali
Property.Methylene chloride extraction, collected organic layer, anhydrous Na2SO4Dry, rotary evaporation removes solvent.Crude product is through silica gel column chromatography point
From purifying (methylene chloride/methanol=30:1, v/v).Obtain (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) ammonia
Base) -4- methyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) t-butyl carbamate
0.294g%.1H NMR(400MHz,CDCl3) δ 8.46 (s, 1H), 8.18 (d, J=8.8Hz, 1H), 7.79 (s, 1H), 7.74
(s, 1H), 7.24-7.20 (m, 3H), 6.69 (s, 1H), 6.54 (d, J=2.4Hz, 1H), 6.50 (dd, J=8.8Hz, J=
2.4Hz, 1H), 4.52 (q, J=6.8Hz, 1H), 3.85 (s, 3H), 3.17 (t, J=4.4Hz, 4H), 2.60 (t, J=4.8Hz,
4H), 2.36 (s, 3H), 1.51 (s, 9H), 1.49 (d, J=6.0Hz, 3H) .LC-MS:m/z:576.3 (M+H)+.
7.N- (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4- methyl-2- oxo-2H-
Pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide (001)
Weigh (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4- methyl-2- oxo-2H-
Pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) t-butyl carbamate (0.277g, 0.48mmol) is mono- in 25mL
Mouth flask is added the dissolution of 6mL methylene chloride, 1mL trifluoroacetic acid is added dropwise, is stirred at room temperature 5 hours.TLC tracks raw material conversion, is added
It is saturated NaHCO3Aqueous solution is neutralized to alkalinity.Methylene chloride extraction, collected organic layer, anhydrous Na2SO4Dry, rotary evaporation removes
Solvent, crude product react in next step without isolating and purifying to be directly used in.
Previous step is taken off into Boc product (0.187g, 0.39mmol) and is dissolved in 5mL methylene chloride, be added triethylamine (0.060g,
0.6mmol), ice bath stirring 10 minutes.Acryloyl chloride (42 μ L, 0.51mmol) separately is taken, 1mL methylene chloride is dissolved in, is added to
It states in reaction solution, is stirred overnight at room temperature.TLC tracks raw material conversion, and saturation NaHCO is added3Aqueous solution is neutralized to alkalinity.Dichloromethane
Alkane extraction, collected organic layer, anhydrous Na2SO4Dry, rotary evaporation removes solvent, and crude product is through silica gel column chromatography separating purification (two
Chloromethanes/methanol=20:1, v/v).Obtain N- (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4-
Methyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide 0.091g.1H NMR
(400MHz,DMSO-d6) δ 10.46 (s, 1H), 8.23 (s, 1H), 7.85 (d, J=8.0Hz, 1H), 7.81 (s, 1H), 7.67
(s, 1H), 7.47 (t, J=8.0Hz, 1H), 7.27 (d, J=8.4Hz, 1H), 7.10 (d, J=8.0Hz, 1H), 6.56 (d, J=
1.2Hz, 1H), 6.48 (dd, J=16.8Hz, J=9.6Hz, 1H), 6.27 (dd, J=17.2Hz, J=1.6Hz, 1H), 6.11-
6.09 (m, 1H), 5.77 (dd, J=16.8Hz, J=1.6Hz, 1H), 5.73 (q, J=6.4Hz, 1H), 3.76 (s, 3H),
3.22-3.20 (m, 4H), 3.02-2.99 (m, 4H), 2.61 (s, 3H), 1.70 (d, J=6.4Hz, 3H) .HRMS (ESI) (m/
z):(M+H)+calcd for C28H32N7O4 530.2516,found,530.2512.
Inventor has made further chiral resolution to gained compound, to obtain following enantiomter:
Following 002-005 compound synthesizes to obtain according to the method for above-mentioned steps a-g:
((7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4- ethyl-2-oxo-2H- are phonetic by 3- by N-
Pyridine simultaneously [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide (002)
1H NMR(400MHz,DMSO-d6) δ 10.46 (s, 1H), 8.22 (s, 1H), 7.85 (d, J=8.4Hz, 1H), 7.81
(s, 1H), 7.66 (s, 1H), 7.47 (t, J=8.0Hz, 1H), 7.26 (d, J=8.4Hz, 1H), 7.09 (d, J=8.0Hz,
1H), 6.55 (d, J=2.0Hz, 1H), 6.48 (dd, J=16.8Hz, J=6.8Hz, 1H), 6.27 (dd, J=16.8Hz, J=
1.6Hz, 1H), 6.10-6.09 (m, 1H), 5.77 (dd, J=10.0Hz, J=1.6Hz, 1H), 5.55 (t, J=6.8Hz, 1H),
3.76 (s, 3H), 3.19 (t, J=4.4Hz, 4H), 2.92 (t, J=4.4Hz, 4H), 2.56 (s, 3H), 2.09-1.95 (m,
2H), 1.03 (t, J=7.2Hz, 3H) .HRMS (ESI) (m/z): (M+H)+calcd for C29H34N7O4 544.2672,
found,544.2654.
Inventor has made further chiral resolution to gained compound, to obtain following enantiomter:
((7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4- propyl-2- oxo-2H- are phonetic by 3- by N-
Pyridine simultaneously [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide (003)
1H NMR(400MHz,DMSO-d6) δ 10.45 (s, 1H), 8.22 (s, 1H), 7.85 (d, J=8.0Hz, 1H), 7.80
(s, 1H), 7.66 (s, 1H), 7.47 (t, J=8.0Hz, 1H), 7.25 (d, J=8.4Hz, 1H), 7.08 (d, J=8.0Hz,
1H), 6.54 (d, J=2.0Hz, 1H), 6.48 (dd, J=16.8Hz, J=10.0Hz, 1H), 6.26 (dd, J=16.8Hz, J=
1.6Hz, 1H), 6.10-6.09 (m, 1H), 5.77 (dd, J=9.6Hz, J=1.6Hz, 1H), 5.60 (t, J=7.2Hz, 1H),
3.76 (s, 3H), 3.14 (t, J=4.4Hz, 4H), 2.79 (t, J=4.4Hz, 4H), 2.47 (s, 3H), 2.00-1.92 (m,
2H), 1.56-1.44 (m, 2H), 0.99 (t, J=7.2Hz, 3H) .HRMS (ESI) (m/z): (M+H)+calcd for
C30H36N7O4 558.2829,found,558.2836.
Inventor has made further chiral resolution to gained compound, to obtain following enantiomter:
N- (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4- isopropyl-2- oxo-2H-
Pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide (004)
1H NMR(400MHz,DMSO-d6) δ 10.52 (s, 1H), 8.22 (s, 1H), 7.87 (d, J=8.0Hz, 1H), 7.85
(s, 1H), 7.64 (s, 1H), 7.47 (t, J=8.0Hz, 1H), 7.26 (d, J=7.6Hz, 1H), 7.05 (d, J=7.6Hz,
1H), 6.57 (d, J=1.6Hz, 1H), 6.50 (dd, J=16.8Hz, J=10.0Hz, 1H), 6.26 (dd, J=16.8Hz, J=
1.6Hz, 1H), 6.14-6.10 (m, 1H), 5.77 (dd, J=10.0Hz, J=1.6Hz, 1H), 5.40 (d, J=4.8Hz, 1H),
3.77 (s, 3H), 3.18 (t, J=4.4Hz, 4H), 2.74 (s, 3H), 2.27-2.22 (m, 1H), 1.04 (d, J=6.8Hz,
3H), 0.99 (d, J=6.8Hz, 3H) .HRMS (ESI) (m/z): (M+H)+calcd for C30H36N7O4 558.2829,
found,558.2831.
Inventor has made further chiral resolution to gained compound, to obtain following enantiomter:
N- (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-2- oxo-2H- pyrimidos [4,
5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide (005)
1H NMR(400MHz,CDCl3+CD3OD) δ 8.09 (s, 1H), 7.89 (s, 1H), 7.75 (d, J=8.4Hz, 1H),
7.47 (t, J=8.0Hz, 1H), 7.42-7.39 (m, 1H), 7.07 (d, J=7.6Hz, 1H), 6.42-6.38 (m, 2H), 6.15
(d, J=7.2Hz, 1H), 5.71 (dd, J=9.2Hz, J=2.8Hz, 1H), 5.36 (s, 2H), 3.80 (s, 3H), 3.37 (t, J
=4.8Hz, 4H), 3.24 (t, J=4.8Hz, 4H), 2.82 (s, 3H) .HRMS (ESI) (m/z): (M+H)+calcd for
C27H30N7O4 516.2359,found,516.2364.
The specific synthetic method of compound 006-008 is as follows:
Reagent and condition: (a) Grignard Reagent, THF, 0 DEG C, 6h；(b)CDI,K2CO3, THF, reflux, overnight；(c) aryl
Amine, trifluoroacetic acid, trifluoroethanol, reflux, for 24 hours；(d) trifluoroacetic acid, CH2Cl2, room temperature, 5h；(e) acryloyl chloride, Et3N,
CH2Cl2, 0 DEG C is arrived room temperature, overnight.
(1. 3- ((the chloro- 5- of 2- (2- hydroxyl propyl- 2- yl) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate
Weigh 4- ((3- ((tert-butoxycarbonyl) amino) phenyl) amino) -2- chlorine pyrimidine -5- Ethyl formate (2.352g,
6mmol) in 50mL two mouth flask, the dissolution of 20mL anhydrous tetrahydro furan is added, argon gas is protected, and ice bath stirring 10 minutes.Separately take first
Base magnesium bromide (1M in THF, 24mL), is slowly added into above-mentioned reaction solution, drips ice bath stirring 6 hours.TLC tracking is former
Reaction solution is poured into 50mL saturation NH by material conversion4In Cl aqueous solution, ethyl acetate extraction, collected organic layer, anhydrous Na2SO4It is dry
Dry, rotary evaporation removes solvent.Crude product is through silica gel column chromatography separating purification (petrol ether/ethyl acetate=2.5:1, v/v).?
(3- ((the chloro- 5- of 2- (2- hydroxyl propyl- 2- yl) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate 1.586g.1H NMR
(400MHz,DMSO-d6) δ 10.01 (s, 1H), 9.41 (s, 1H), 8.12 (s, 1H), 7.62 (t, J=2.0Hz, 1H), 7.40
(dd, J=8.0Hz, J=1.2Hz, 1H), 7.25 (t, J=8.4Hz, 1H), 7.13 (d, J=8.8Hz, 1H), 6.43 (s, 1H),
1.56(s,6H),1.48(s,9H).LC-MS:m/z:379.1(M+H)+.
(2. 3- (chloro- 4,4- dimethyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (the 4H)-yl of 7-) phenyl)
T-butyl carbamate
Weigh (3- ((the chloro- 5- of 2- (2- hydroxyl propyl- 2- yl) pyrimidine-4-yl) amino) phenyl) t-butyl carbamate
(1.512g, 4mmol), potassium carbonate (0.828g, 6mmol), 1,1'- carbonyl dimidazoles (1.296g, 8mmol) are burnt in 25mL single port
Bottle is added 10mL anhydrous tetrahydro furan, is refluxed overnight.TLC tracks raw material conversion, and ice water, methylene chloride extraction is added, and collection has
Machine layer, anhydrous Na2SO4Dry, rotary evaporation removes solvent.Crude product is through silica gel column chromatography separating purification (petrol ether/ethyl acetate
=2.5:1, v/v).Obtain (3- (chloro- 4,4- dimethyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (the 4H)-yl of 7-)
Phenyl) t-butyl carbamate 1.049g.1H NMR(400MHz,DMSO-d6)δ9.57(s,1H),8.64(s,1H),7.57(s,
1H),7.41-7.36(m,2H),7.01-6.99(m,1H),1.79(s,6H),1.47(s,9H).LC-MS:m/z:405.1(M+
H)+.
3. (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4,4- dimethyl-2- oxos-
2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) t-butyl carbamate
Weigh (3- (chloro- 4,4- dimethyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (the 4H)-yl of 7-) benzene
Base) t-butyl carbamate (1.010g, 2.5mmol), 2- methoxyl group -4- (4- methylpiperazine-1-yl) aniline (0.663g,
3mmol) in 50mL two mouth flask, the dissolution of 15mL trifluoroethanol is added, is added dropwise trifluoroacetic acid (280 μ L, 3.77mmol), argon gas is protected
Shield, temperature rising reflux 24 hours.TLC tracks raw material conversion, is cooled to room temperature, and saturation NaHCO is added3Aqueous solution is neutralized to alkalinity.
Methylene chloride extraction, collected organic layer, anhydrous Na2SO4Dry, rotary evaporation removes solvent.Crude product separates pure through silica gel column chromatography
Change (methylene chloride/methanol=25:1, v/v).Obtain (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-
4,4- dimethyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) t-butyl carbamate
0.516g。1H NMR(400MHz,CDCl3) δ 8.07 (s, 1H), 7.51 (d, J=8.4Hz, 2H), 7.47-7.43 (m, 2H),
7.01 (d, J=7.2Hz, 1H), 6.45 (s, 1H), 6.44 (d, J=2.4Hz, 1H), 6.18-6.16 (m, 1H), 3.82 (s,
3H), 3.16 (t, J=4.4Hz, 4H), 2.67 (t, J=4.4Hz, 4H), 2.42 (s, 3H), 1.80 (s, 6H), 1.49 (s, 9H)
.LC-MS:m/z:590.4(M+H)+.
4.N- (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4,4- dimethyl-2- oxos-
2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide (006)
Weigh (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4,4- dimethyl-2- oxos-
2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) t-butyl carbamate (0.500g, 0.85mmol) is in 25mL
Single-necked flask is added the dissolution of 6mL methylene chloride, 1mL trifluoroacetic acid is added dropwise, is stirred at room temperature 5 hours.TLC tracks raw material conversion, adds
Enter to be saturated NaHCO3Aqueous solution is neutralized to alkalinity.Methylene chloride extraction, collected organic layer, anhydrous Na2SO4Dry, rotary evaporation removes
Solvent is removed, crude product reacts in next step without isolating and purifying to be directly used in.
Previous step is taken off into Boc product (0.335g, 0.68mmol) and is dissolved in 5mL methylene chloride, be added triethylamine (0.102g,
1.02mmol), ice bath stirring 10 minutes.Acryloyl chloride (72 μ L, 0.88mmol) separately is taken, 1mL methylene chloride is dissolved in, is added to
It states in reaction solution, is stirred overnight at room temperature.TLC tracks raw material conversion, and saturation NaHCO is added3Aqueous solution is neutralized to alkalinity.Dichloromethane
Alkane extraction, collected organic layer, anhydrous Na2SO4Dry, rotary evaporation removes solvent, and crude product is through silica gel column chromatography separating purification (two
Chloromethanes/methanol=20:1, v/v).N- (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4,
4- dimethyl -2- oxo -2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide 0.165g.1H NMR
(400MHz,CDCl3) δ 8.08 (s, 1H), 7.79 (d, J=8.0Hz, 1H), 7.74 (s, 1H), 7.47 (t, J=8.0Hz, 1H),
7.38-7.36 (m, 1H), 7.05 (d, J=7.6Hz, 1H), 6.41 (d, J=2.0Hz, 1H), 6.36-6.33 (m, 2H), 6.13
(s, 1H), 5.70 (dd, J=9.2Hz, J=2.4Hz, 1H), 3.80 (s, 3H), 3.17 (t, J=4.4Hz, 4H), 2.80 (t, J
=4.4Hz, 4H), 2.50 (s, 3H), 1.80 (s, 6H) .HRMS (ESI) (m/z): (M+H)+calcd for C29H34N7O4
544.2672,found,544.2698.
007 and 008 compound synthesizes to obtain according to the method for above-mentioned steps a-e below:
N- (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4,4- diethyl-2- oxos-
2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide (007)
1H NMR(400MHz,CDCl3) δ 9.42 (s, 1H), 7.96 (s, 1H), 7.89 (s, 1H), 7.81 (d, J=5.6Hz,
1H), 7.53 (s, 1H), 7.42 (t, J=8.0Hz, 1H), 7.33-7.31 (m, 1H), 6.99 (d, J=7.6Hz, 1H), 6.55-
6.49 (m, 1H), 6.36-6.32 (m, 2H), 6.12 (d, J=7.6Hz, 1H), 5.65 (d, J=10.4Hz, 1H), 3.78 (s,
3H), 3.41 (t, J=4.4Hz, 4H), 3.21 (t, J=4.4Hz, 4H), 2.80 (s, 3H), 2.11-1.96 (m, 4H), 1.00
(t, J=7.2Hz, 6H) .HRMS (ESI) (m/z): (M+H)+calcd for C31H38N7O4 572.2985,found,
572.2981.
N- (3- (7-((2- methoxyl group-4- (4- methylpiperazine-1-yl) phenyl) amino)-4,4- diisopropyl base-2- oxygen
Generation -2H- pyrimido [4,5-d] [1,3] oxazines -1 (4H)-yl) phenyl) acrylamide (008)
1H NMR(400MHz,CDCl3) δ 8.06 (s, 1H), 7.96 (s, 1H), 7.77 (d, J=4.8Hz, 1H), 7.49 (s,
1H), 7.41 (t, J=8.0Hz, 1H), 6.97 (d, J=8.0Hz, 1H), 6.40 (d, J=2.0Hz, 1H), 6.36 (dd, J=
16.8Hz, J=1.2Hz, 1H), 6.18-6.12 (m, 2H), 5.68 (dd, J=10.4Hz, J=1.2Hz, 1H), 3.79 (s,
3H), 3.09 (t, J=4.4Hz, 4H), 2.58 (t, J=4.8Hz, 4H), 2.36 (s, 3H), 2.07-2.00 (m, 2H), 1.96-
1.89 (m, 2H), 1.54-1.38 (m, 4H), 0.97 (t, J=7.2Hz, 6H) .HRMS (ESI) (m/z): (M+H)+calcd for
C33H42N7O4 600.3298,found,600.3297.
2. biological activity test of embodiment
Compound provided by the invention is following to the extracorporeal extracorporeal suppression experiment of EGFR kinase activity to carry out:
External enzyme activity assay: wild type and saltant type (L858/T790M) EGFR are purchased from Invitrogen.For institute
The compound to be tested having is provided with from 5.1 × 10-11Mol/L to 1.0 × 10-610 concentration gradients of mol/L.
The concentration of different kinases is tested by optimization and is determined, corresponding concentration are as follows: EGFR (PV3872, Invitrogen)
0.287μg/μL,EGFR-L858R/T790M(PV4879,Invitrogen)0.055μg/μL.Compound in DMSO from
5.1x10-9M to 1x10-4M dilutes three times.4 μ L compounds are dissolved in 96 μ L water, obtain the compound solution of 4x.40 μM of ATP are dissolved in
1.33x kinase buffer liquid, kinases/peptide mixer are ready to for use comprising 2x kinases, 4 μM of trorsine 14 peptides.10 μ L kinase reaction packets
Include 2.5 μ L compound solutions, 5 μ L kinases/peptide mixer, 2.5 μ L ATP solution.5 μ L Phosphorylated Peptide solution are mixed instead of kinases/peptide
Object is closed to compare as 100% phosphorylation.2.5 μ L 1.33x kinase buffer liquids replace ATP solution to inhibit to compare as 100%, and 2.5
μ L 4%DMSO replaces compound solution to be used as 0% inhibition control.It is small that 1.5 are cultivated after solution is sufficiently mixed in plate at room temperature
When.Every hole continues to cultivate at room temperature 1 hour after 5 μ L Development Solution are added, and non-phosphorylated peptide is in this time
Inside it is cleaved.Finally, 5 μ L termination preparation (Stop Reagent) is added, reaction was completed.Orifice plate EnVisionMultilabel
Reader (Perkin Elmer) is measured.Experimental data is calculated using GraphPad Prism version 4.0.
Experiment is repeated 3 times above every time.
Cell Proliferation and growth inhibition analysis: H1975 (non-small cell lung cancer cell, EGFRL858R/T790M), A431 it is (non-small
Cell lung cancer cell, EGFR wild type), cell is obtained from ATCC.Cell-proliferation activity is assessed using MTS analytic approach.
Cell exposure under processing conditions 72 hours, each cell line tests used cell number according to absorbance value (at 490nm every time
Absorbance value be 1.3-2.2) be adjusted.6 concentration gradients (0.1nM-10 μM) are provided with for compound to be tested, each
Concentration value at least uses 6 groups of parallel controls.
H1975, A431 cell are cultivated in corresponding culture medium, and cell at least passes on twice after recovery, are subsequently used for
Experiment uses.The cell of logarithmic phase is by trypsin acting and settling flux in the medium.H1975 (every 1000 cell of hole),
A431 (every 2000 cell of hole) is seeded in 96 orifice plates, 100 μ L of volume；6 groups of parallel and 7 column are set.Orifice plate is put in 37 DEG C 5%
In the incubator of carbon dioxide overnight.Compound is dissolved in DMSO, compound concentration is 10 μM every liter, then by compound concentration by
The compound concentration that step dilution obtains is respectively every liter 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM.2 μ Lization
Polymer solution is added in the culture medium of 998 μ L, and mixture is adequately mixed.The mixture of 100 μ L is added in 96 orifice plates.2μL
DMSO replaces compound solution to be used as 0% inhibition control.After culture 68 hours, 20 μ L MTT (5mg/mL) are added.4 hours
It waits, abandon supernatant and 150 μ L DMSO is added.After shake 10 minutes, orifice plate is with Synergy HT (Bio TeK) (OD490)
Read data.Data are calculated using GraphPad Prism version 4.0, IC50Value is by using dose-effect curve
Nonlinear regression model (NLRM) adjust to obtain.
Test result is as follows shown in table 1.
Table 1
It discusses:
Inventor after extensive and in-depth study, designs and synthesizes to have obtained a series of structures and has no reported in the literature 1,
4- dihydro -2H- pyrimido [4,5-d] [1,3] oxazines -2- ketone compounds, to obtained compound carried out molecular level and
The active testing of cellular level obtains the compound that a batch is capable of selective depression EGFR T790M mutation.The present inventor is into one
Step discovery, proliferation of the compound of the present invention to EGFR saltant type cancer cell (H1975) and EGFR wild type cancer cell (A431)
Rejection ability difference is higher than to mutant egf R and Wild type EGFR kinase activity rejection ability difference, to prompt of the invention
Compound has better difference toxicity in vivo, it is possible to become selective depression T790M and be mutated, overcome the third of clinical drug-resistant
Activity is obtained more preferably and/or the base of difference toxicity more preferably compound for EGFR targeted drug, or as through further modification
Plinth.
All references mentioned in the present invention is incorporated herein by reference, independent just as each document
It is incorporated as with reference to such.In addition, it should also be understood that, after reading the above teachings of the present invention, those skilled in the art can
To make various changes or modifications to the present invention, such equivalent forms equally fall within model defined by the application the appended claims
It encloses.
Claims (10)
1. general formula III compound represented or its pharmaceutically acceptable salt:
In formula,
R2It is selected from
R3、R4It is each independently selected from H or C1-C6Alkyl；
R5、R6、R7、R8And R9It is independently selected from the following group:
2. compound as described in claim 1 or its optical isomer or pharmaceutically acceptable salt, which is characterized in that described
C1-C6Alkyl is methyl or ethyl.
3. compound as described in claim 1 or its pharmaceutically acceptable salt, which is characterized in that R6、R8And R9For H.
4. compound selected from the group below or its optical isomer or pharmaceutically acceptable salt:
5. compound as claimed in claim 4 or its optical isomer or pharmaceutically acceptable salt, the compound are selected from
The following group:
6. a kind of pharmaceutical composition, described pharmaceutical composition contains compound of any of claims 1-5 or its medicine
Acceptable salt and pharmaceutically acceptable carrier or excipient on.
7. compound of any of claims 1-5 treats or prevents the disease that EGFR is mediated in preparation, or inhibits
Purposes in the drug of EGFR.
8. purposes as claimed in claim 7, which is characterized in that the disease that the EGFR is mediated is cancer.
9. purposes as claimed in claim 8, which is characterized in that the cancer is selected from the group: leukaemia, multiple bone marrow cancer and
Solid tumor.
10. purposes as claimed in claim 9, which is characterized in that the solid tumor is selected from the group: non-small cell lung cancer, small thin
Born of the same parents' lung cancer, adenocarcinoma of lung, lung squamous cancer, breast cancer, prostate cancer, neurogliocytoma, oophoroma, G. cephalantha, cervical carcinoma,
The cancer of the esophagus, liver cancer, kidney, cancer of pancreas, colon cancer, cutaneum carcinoma, lymthoma and gastric cancer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610107775.8A CN107129506B (en) | 2016-02-26 | 2016-02-26 | As pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives of EGFR inhibitor and its application |
| PCT/CN2017/075037 WO2017144025A1 (en) | 2016-02-26 | 2017-02-27 | Pyrimido[4,5-d][1,3]oxazin-2-one derivative serving as egfr inhibitor, and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610107775.8A CN107129506B (en) | 2016-02-26 | 2016-02-26 | As pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives of EGFR inhibitor and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107129506A CN107129506A (en) | 2017-09-05 |
| CN107129506B true CN107129506B (en) | 2019-10-22 |
Family
ID=59684744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610107775.8A Active CN107129506B (en) | 2016-02-26 | 2016-02-26 | As pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives of EGFR inhibitor and its application |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107129506B (en) |
| WO (1) | WO2017144025A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721298A (en) * | 2017-04-19 | 2018-11-02 | 华东理工大学 | As the pyrimido heterocyclic compound of bruton's tyrosine kinase inhibitor and its application |
| CN110372666B (en) * | 2018-04-13 | 2022-11-08 | 华东理工大学 | Quinazoline compound as EGFR (epidermal growth factor receptor) triple mutation inhibitor and application thereof |
| CN113801139A (en) * | 2020-06-12 | 2021-12-17 | 华东理工大学 | Pyrimido-oxazine derivatives as RSK inhibitors and uses thereof |
| CN115160340B (en) * | 2022-06-07 | 2023-07-21 | 四川大学华西医院 | Small molecular compound with ACK1 inhibition activity and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002058695A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| CN102816162A (en) * | 2011-06-10 | 2012-12-12 | 中国科学院广州生物医药与健康研究院 | Pyrimidine, pyrimidone compound, and medical compound and application thereof |
| CN103421010A (en) * | 2012-05-14 | 2013-12-04 | 华东理工大学 | Pteridinone derivative as EGFR inhibitor and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218561B (en) * | 2014-06-25 | 2018-10-30 | 上海艾力斯医药科技有限公司 | Annelated pyrimidines ring derivatives, preparation method and application |
| CN105985342B (en) * | 2015-02-06 | 2018-07-24 | 华东理工大学 | As the pyrimido-pyrimidine derovatives of EGFR inhibitor and its application |
| CN106279173A (en) * | 2015-05-29 | 2017-01-04 | 华东理工大学 | Pteridinone derivant is as the application of EGFR inhibitor |
-
2016
- 2016-02-26 CN CN201610107775.8A patent/CN107129506B/en active Active
-
2017
- 2017-02-27 WO PCT/CN2017/075037 patent/WO2017144025A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002058695A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| CN102816162A (en) * | 2011-06-10 | 2012-12-12 | 中国科学院广州生物医药与健康研究院 | Pyrimidine, pyrimidone compound, and medical compound and application thereof |
| CN103421010A (en) * | 2012-05-14 | 2013-12-04 | 华东理工大学 | Pteridinone derivative as EGFR inhibitor and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017144025A1 (en) | 2017-08-31 |
| CN107129506A (en) | 2017-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105985342B (en) | As the pyrimido-pyrimidine derovatives of EGFR inhibitor and its application | |
| JP6114820B2 (en) | Pteridinone derivatives and applications as inhibitors of EGFR, BLK, FLT3 | |
| EP3312180B1 (en) | Use of pteridinone derivative serving as egfr inhibitor | |
| CN107129506B (en) | As pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives of EGFR inhibitor and its application | |
| CN105646454B (en) | The 2- aryl amine pyridine derivatives of the fragment containing hydroxamic acid and preparation and application | |
| CN107021937B (en) | Benzothiazole Carbox amide and its application | |
| CN109096250A (en) | 4- phenoxypyridines class compound and its application containing pyridazinone | |
| JP2022517723A (en) | Macrocycle compound as a CDK inhibitor, its production method and its application in pharmaceutical products | |
| WO2020224626A1 (en) | Compound used as kinase inhibitor and application thereof | |
| CN106892922B (en) | As the 5,8- dihydropteridine -6,7- derovatives of EGFR inhibitor and its application | |
| CN110724137B (en) | Thiophene derivative and preparation method and application thereof | |
| CN105330653A (en) | Quinazoline derivatives | |
| CN110283162B (en) | Epidermal growth factor receptor inhibitor and application thereof | |
| CN109988151A (en) | A kind of acetylene compound, preparation method and applications | |
| Wang et al. | Design, synthesis and anti-tumor efficacy of novel phenyl thiazole/triazole derivatives as selective TrkA inhibitors | |
| CN107513040A (en) | Substitute the preparation of benzo pyridine compound and the application of molecular targeted anti-tumor medicine | |
| CN107903248A (en) | The Isatine derivatives of N substitution isatin heterozygosis quinazoline compounds synthesis and the application in antitumor drug is prepared | |
| CN106478700B (en) | Boron-substituted aniline protein kinase inhibitor | |
| WO2023046114A1 (en) | Pteridinone derivative and use thereof | |
| CN110066274B (en) | Pyridine-2-formic acid derivative and preparation method and application thereof | |
| CN109912620B (en) | Tetrahydrobenzo [4,5] thieno [2,3-d ] pyrimidine compound and application thereof | |
| CN118146164A (en) | Hydrazone-containing quinazoline derivative or pharmaceutically acceptable salt thereof, and preparation method and application thereof | |
| CN105061461B (en) | Tetrahydro benzo [4,5] thieno [2,3 d] pyrimidines and its application containing benzylamine structure | |
| CN117986184A (en) | N-substituted pyridone compounds, preparation method and pharmaceutical application thereof | |
| CN115215848A (en) | Protein kinase inhibitor and derivative, preparation method, pharmaceutical composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |